Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Pose

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Journal of Hepatology|April 23, 2023
Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogrammingBeatriz Aguilar-Bravo, Silvia Ariño, Delia Blaya, et al.
The Lancet. Gastroenterology & Hepatology|October 15, 2019
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trialElisa Pose, Laura Napoleone, Ahmed Amin, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 2, 2025
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical PracticeLuis Antonio Diaz, Veeral Ajmera, Juan Pablo Arab, et al.
Hepatology Communications|December 29, 2021
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated CirrhosisElisa Pose, Elsa Solà, Juan J Lozano, et al.
Hepatology (Baltimore, Md.)|April 5, 2020
Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic HepatitisTejasav S Sehrawat, Juan P Arab, Mengfei Liu, et al.
Nature Reviews. Gastroenterology & Hepatology|September 27, 2025
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver diseaseLuis Antonio Diaz, Maja Thiele, Alexandre Louvet, et al.
Journal of Hepatology|October 9, 2020
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry studyThomas Marjot, Andrew M Moon, Jonathan A Cook, et al.
Journal of Hepatology|November 28, 2024
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver diseaseJuan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.
Hepatology (Baltimore, Md.)|December 6, 2024
Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damageIrene González-Recio, Naroa Goikoetxea-Usandizaga, Claudia M Rejano-Gordillo, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Journal of Hepatology|April 23, 2023
Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogrammingBeatriz Aguilar-Bravo, Silvia Ariño, Delia Blaya, et al.
The Lancet. Gastroenterology & Hepatology|October 15, 2019
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trialElisa Pose, Laura Napoleone, Ahmed Amin, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 2, 2025
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical PracticeLuis Antonio Diaz, Veeral Ajmera, Juan Pablo Arab, et al.
Hepatology Communications|December 29, 2021
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated CirrhosisElisa Pose, Elsa Solà, Juan J Lozano, et al.
Hepatology (Baltimore, Md.)|April 5, 2020
Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic HepatitisTejasav S Sehrawat, Juan P Arab, Mengfei Liu, et al.
Nature Reviews. Gastroenterology & Hepatology|September 27, 2025
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver diseaseLuis Antonio Diaz, Maja Thiele, Alexandre Louvet, et al.
Journal of Hepatology|October 9, 2020
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry studyThomas Marjot, Andrew M Moon, Jonathan A Cook, et al.
Journal of Hepatology|November 28, 2024
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver diseaseJuan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.
Hepatology (Baltimore, Md.)|December 6, 2024
Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damageIrene González-Recio, Naroa Goikoetxea-Usandizaga, Claudia M Rejano-Gordillo, et al.
Pageof 10